-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – EP-547 in Uremic (Renal) Pruritus
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - EP-547 in Uremic (Renal) Pruritus report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. EP-547 in Uremic (Renal) Pruritus Drug Details: EP-547 is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Pacmilimab in Pancreatic Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Pacmilimab in Pancreatic Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Pacmilimab in Pancreatic Cancer Drug Details: CX-072 is under development for...
-
Product Insights
NewHepatitis C – Drugs In Development, 2024
Empower your strategies with our Hepatitis C – Drugs In Development, 2024 report and make more profitable business decisions. Hepatitis C is a contagious viral infection affecting the liver. It spreads on contact with infected blood. It may be a mild condition or may be chronic, leading to various complications. The characteristic symptoms include abdominal pain, fatigue, fever, jaundice, loss of appetite, nausea, and vomiting. The predisposing factors of hepatitis C include dialysis, organ transplant, and blood transfusion. The offspring of...
-
Product Insights
NewPruritus – Drugs In Development, 2024
Empower your strategies with our Pruritus – Drugs In Development, 2024 report and make more profitable business decisions. Pruritus, or itch, is defined as an unpleasant sensation that provokes the desire to scratch. Pruritus is caused by cancer, cancer treatments, infection, dry skin, and reactions to drugs. Symptoms include redness, bumps, spots or blisters, dry, cracked skin, and leathery or scaly texture to the skin. Risk factors include heat, allergies, asthma, hay fever, hives, and eczema. Treatment includes corticosteroids, antihistamines, and...
-
Product Insights
NewChronic Urticaria Or Hives – Drugs In Development, 2024
Empower your strategies with our Chronic Urticaria Or Hives – Drugs In Development, 2024 report and make more profitable business decisions. Chronic urticaria, also known as hives, are outbreaks of swollen, pale red bumps, patches, or welts on the skin that appear suddenly either as a result of allergies, or for other reasons. The main symptom is itchy rashes. Chronic urticaria occurs when histamine and other chemicals are released from under the skin's surface, causing the tissues to swell. Predisposing factors...
-
Product Insights
NewUremic (Renal) Pruritus – Drugs In Development, 2024
Empower your strategies with our Uremic (Renal) Pruritus – Drugs In Development, 2024 report and make more profitable business decisions. Uremic pruritis is a condition where there is presence of excess urea in the blood associated with itchiness (pruritis). It is associated with chronic kidney disease (CKD). Most common in end stage CKD and patients on hemodialysis. Underlying diseases (CKD), diabetes, inflammation, uremic toxins are common triggering factors affecting 20-25% of body surface area and is associated with itchiness, secondary skin...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – EP-262 in Chronic Urticaria Or Hives
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - EP-262 in Chronic Urticaria Or Hives report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. EP-262 in Chronic Urticaria Or Hives Drug Details: EP-262 is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – EP-262 in Atopic Dermatitis (Atopic Eczema)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - EP-262 in Atopic Dermatitis (Atopic Eczema) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. EP-262 in Atopic Dermatitis (Atopic Eczema) Drug Details: EP-262 is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – EP-547 in Hepatitis B
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. EP-547 in Hepatitis B Drug Details: EP-547 is under developmant for the treatment of cholestatic pruritus...